-- Alcon takes over development of POT-4 as a treatment for patients with age-related macular degeneration -- Deal provides path for Alcon to acquire Potentia LOUISVILLE, Ky., Oct. 23...
Presentation to be Webcast on September 29, 2009 EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY) http://www.novabaypharma.com/, a clinical...
In the news release, Agency.com Helps Launch the New Alcon.com, issued earlier today by Agency.com over PR Newswire, we are advised by the company that the phone number in the contact...
Alcon Views AMO Patent Lawsuit as Meritless FORT WORTH, Texas, Dec. 16 /PRNewswire-FirstCall/ -- On December 3, 2003, Advanced Medical Optics (AMO) filed a complaint against Alcon Laboratories...
RNS Number:8575S Acal PLC 04 December 2003 Appointment of Mr Graham Williams as a Non-Executive Director On 1st December 2003 Acal plc announced the appointment of Mr Graham Williams...
RNS Number:6614S Acal PLC 01 December 2003 FOR RELEASE 7:00AM 1 DECEMBER 2003 ACAL plc (Leading pan-European, value added distributor providing specialist design-in, sales and...
RNS Number:9575R Acal PLC 12 November 2003 FOR RELEASE 7.00AM 12 NOVEMBER 2003 ACAL PLC (Acal is a leading European value-added distributor providing specialist design-in, sales...
RNS Number:9135R Acal PLC 11 November 2003 Acal plc (the "Company") received notice on 10 November 2003 that, for the purposes of Part VI of the Companies Act 1985 (as amended) Prudential...
RNS Number:4111R Acal PLC 28 October 2003 Acal PLC 28 October 2003 Schedule 10 - Notification of Major Interests in Shares On 27 October 2003 the Company received the following...
RNS Number:9053Q Acal PLC 14 October 2003 BLOCKLISTING SIX MONTHLY REVIEW 1. NAME OF COMPANY: ACAL PLC 2. NAME OF SCHEME: ACAL EXECUTIVE SHARE OPTION SCHEME 3. PERIOD...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales